MARKET

VIRI

VIRI

Virios Therapeutics, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.56
-0.09
-1.35%
After Hours: 6.63 +0.07 +1.07% 16:18 01/21 EST
OPEN
7.04
PREV CLOSE
6.65
HIGH
7.04
LOW
6.19
VOLUME
25.39K
TURNOVER
--
52 WEEK HIGH
8.79
52 WEEK LOW
4.000
MARKET CAP
51.38M
P/E (TTM)
-3.2107
1D
5D
1M
3M
1Y
5Y
BRIEF-Virios Therapeutics - Has Withdrawn Application For IND Focused On Treatment Of Irritable Bowel Syndrome By Its Lead Compound, IMC-1
reuters.com · 12/17/2021 14:44
HC Wainwright & Co. Initiates Coverage On Virios Therapeutics with Buy Rating, Announces Price Target of $12
HC Wainwright & Co. analyst Sean Lee initiates coverage on Virios Therapeutics (NASDAQ:VIRI) with a Buy rating and announces Price Target of $12.
Benzinga · 12/15/2021 11:07
BRIEF-Virios Therapeutics Achieves Over 50% Enrollment Milestone In Its Phase 2B Clinical Trial For Fibromyalgia
reuters.com · 12/01/2021 12:24
Virios Therapeutics Announced Over 50% Enrollment Milestone in its Phase 2b Clinical Trial for Fibromyalgia
Virios Therapeutics, Inc.
Benzinga · 12/01/2021 12:06
VIRI: Filed IND for IMC-1 in Irritable Bowel Syndrome…
By David Bautz, PhD NASDAQ:VIRI READ THE FULL VIRI RESEARCH REPORT Business Update Update on Phase 2b FORTRESS Trial Virios Therapeutics, Inc. (NASDAQ:VIRI) is currently conducting the Phase 2b FORTRESS (Fibromyalgia Outcome Research Trial Evaluating Syner...
Zacks Small Cap Research · 11/15/2021 12:34
Virios Therapeutics Q3 EPS $(0.49) Beats $(0.69) Estimate
Virios Therapeutics (NASDAQ:VIRI) reported quarterly losses of $(0.49) per share which beat the analyst consensus estimate of $(0.69) by 28.99 percent.
Benzinga · 11/11/2021 12:13
BRIEF-Virios Therapeutics Announces Third Quarter 2021 Financial Results
reuters.com · 11/11/2021 12:12
Virios Therapeutics EPS beats by $0.21
Virios Therapeutics (NASDAQ:VIRI): Q3 GAAP EPS of -$0.49 beats by $0.21. As of September 30, 2021, cash totaled $19.2M. The Company believes it will have sufficient resources to fund planned
Seekingalpha · 11/11/2021 12:12
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VIRI. Analyze the recent business situations of Virios Therapeutics, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average VIRI stock price target is 16.33 with a high estimate of 22.00 and a low estimate of 12.00.
High22.00
Average16.33
Low12.00
Current 6.56
EPS
Actual
Estimate
-0.55-0.41-0.28-0.14
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 13
Institutional Holdings: 1.00M
% Owned: 12.80%
Shares Outstanding: 7.83M
TypeInstitutionsShares
Increased
8
69.83K
New
4
94.14K
Decreased
1
11.35K
Sold Out
4
37.28K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
About VIRI
Virios Therapeutics, Inc., formerly Virios Therapeutics, LLC., is a development-stage biotechnology company focused on advancing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia (FM). Its lead development candidate is IMC-1, which is a fixed dose combination of famciclovir and celecoxib. IMC-1 represents a combination antiviral therapy designed to synergistically suppress Herpes Simplex Virus-1 (HSV-1) activation and replication. Its HSV-1 root cause of chronic illnesses such as FM, irritable bowel disease (IBS), chronic fatigue syndrome and functional somatic syndrome. The Company is developing its initial candidate, IMC-1, for people who are suffering from fibromyalgia.

Webull offers kinds of Virios Therapeutics Inc stock information, including NASDAQ:VIRI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VIRI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VIRI stock methods without spending real money on the virtual paper trading platform.